Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series

Patrizio P Caturegli, Giulia Di Dalmazi, Martina Lombardi, Federica Grosso, Harry Larman, Tatianna Larman, Giacomo Taverna, Mirco Cosottini, Isabella Lupi

Research output: Contribution to journalArticle

Abstract

Hypophysitis that develops in cancer patients treated with monoclonal antibodies blocking cytotoxic T-lymphocyte–associated protein 4 (CTLA-4; an inhibitory molecule classically expressed on T cells) is now reported at an incidence of approximately 10%. Its pathogenesis is unknown, in part because no pathologic examination of the pituitary gland has been reported to date. We analyzed at autopsy the pituitary glands of six cancer patients treated with CTLA-4 blockade, one with clinical and pathologic evidence of hypophysitis, one with mild lymphocytic infiltration in the pituitary gland but no clinical signs of hypophysitis, and four with normal pituitary structure and function. CTLA-4 antigen was expressed by pituitary endocrine cells in all patients but at different levels. The highest levels were found in the patient who had clinical and pathologic evidence of severe hypophysitis. This high pituitary CTLA-4 expression was associated with T-cell infiltration and IgG-dependent complement fixation and phagocytosis, immune reactions that induced an extensive destruction of the adenohypophyseal architecture. Pituitary CTLA-4 expression was confirmed in a validation group of 37 surgical pituitary adenomas and 11 normal pituitary glands. The study suggests that administration of CTLA-4 blocking antibodies to patients who express high levels of CTLA-4 antigen in the pituitary can cause an aggressive (necrotizing) form of hypophysitis through type IV (T-cell dependent) and type II (IgG dependent) immune mechanisms.

Original languageEnglish (US)
Pages (from-to)3225-3235
Number of pages11
JournalAmerican Journal of Pathology
Volume186
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Autopsy
Pituitary Gland
CTLA-4 Antigen
Proteins
T-Lymphocytes
Immunoglobulin G
Blocking Antibodies
Endocrine Cells
Pituitary Neoplasms
Phagocytosis
Neoplasms
Monoclonal Antibodies
Hypophysitis
Incidence

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade : Insights into Pathogenesis from an Autopsy Series. / Caturegli, Patrizio P; Di Dalmazi, Giulia; Lombardi, Martina; Grosso, Federica; Larman, Harry; Larman, Tatianna; Taverna, Giacomo; Cosottini, Mirco; Lupi, Isabella.

In: American Journal of Pathology, Vol. 186, No. 12, 01.12.2016, p. 3225-3235.

Research output: Contribution to journalArticle

Caturegli, Patrizio P ; Di Dalmazi, Giulia ; Lombardi, Martina ; Grosso, Federica ; Larman, Harry ; Larman, Tatianna ; Taverna, Giacomo ; Cosottini, Mirco ; Lupi, Isabella. / Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade : Insights into Pathogenesis from an Autopsy Series. In: American Journal of Pathology. 2016 ; Vol. 186, No. 12. pp. 3225-3235.
@article{ef68a8ec29da44b5baef0d738ce5798f,
title = "Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series",
abstract = "Hypophysitis that develops in cancer patients treated with monoclonal antibodies blocking cytotoxic T-lymphocyte–associated protein 4 (CTLA-4; an inhibitory molecule classically expressed on T cells) is now reported at an incidence of approximately 10{\%}. Its pathogenesis is unknown, in part because no pathologic examination of the pituitary gland has been reported to date. We analyzed at autopsy the pituitary glands of six cancer patients treated with CTLA-4 blockade, one with clinical and pathologic evidence of hypophysitis, one with mild lymphocytic infiltration in the pituitary gland but no clinical signs of hypophysitis, and four with normal pituitary structure and function. CTLA-4 antigen was expressed by pituitary endocrine cells in all patients but at different levels. The highest levels were found in the patient who had clinical and pathologic evidence of severe hypophysitis. This high pituitary CTLA-4 expression was associated with T-cell infiltration and IgG-dependent complement fixation and phagocytosis, immune reactions that induced an extensive destruction of the adenohypophyseal architecture. Pituitary CTLA-4 expression was confirmed in a validation group of 37 surgical pituitary adenomas and 11 normal pituitary glands. The study suggests that administration of CTLA-4 blocking antibodies to patients who express high levels of CTLA-4 antigen in the pituitary can cause an aggressive (necrotizing) form of hypophysitis through type IV (T-cell dependent) and type II (IgG dependent) immune mechanisms.",
author = "Caturegli, {Patrizio P} and {Di Dalmazi}, Giulia and Martina Lombardi and Federica Grosso and Harry Larman and Tatianna Larman and Giacomo Taverna and Mirco Cosottini and Isabella Lupi",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.ajpath.2016.08.020",
language = "English (US)",
volume = "186",
pages = "3225--3235",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade

T2 - Insights into Pathogenesis from an Autopsy Series

AU - Caturegli, Patrizio P

AU - Di Dalmazi, Giulia

AU - Lombardi, Martina

AU - Grosso, Federica

AU - Larman, Harry

AU - Larman, Tatianna

AU - Taverna, Giacomo

AU - Cosottini, Mirco

AU - Lupi, Isabella

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Hypophysitis that develops in cancer patients treated with monoclonal antibodies blocking cytotoxic T-lymphocyte–associated protein 4 (CTLA-4; an inhibitory molecule classically expressed on T cells) is now reported at an incidence of approximately 10%. Its pathogenesis is unknown, in part because no pathologic examination of the pituitary gland has been reported to date. We analyzed at autopsy the pituitary glands of six cancer patients treated with CTLA-4 blockade, one with clinical and pathologic evidence of hypophysitis, one with mild lymphocytic infiltration in the pituitary gland but no clinical signs of hypophysitis, and four with normal pituitary structure and function. CTLA-4 antigen was expressed by pituitary endocrine cells in all patients but at different levels. The highest levels were found in the patient who had clinical and pathologic evidence of severe hypophysitis. This high pituitary CTLA-4 expression was associated with T-cell infiltration and IgG-dependent complement fixation and phagocytosis, immune reactions that induced an extensive destruction of the adenohypophyseal architecture. Pituitary CTLA-4 expression was confirmed in a validation group of 37 surgical pituitary adenomas and 11 normal pituitary glands. The study suggests that administration of CTLA-4 blocking antibodies to patients who express high levels of CTLA-4 antigen in the pituitary can cause an aggressive (necrotizing) form of hypophysitis through type IV (T-cell dependent) and type II (IgG dependent) immune mechanisms.

AB - Hypophysitis that develops in cancer patients treated with monoclonal antibodies blocking cytotoxic T-lymphocyte–associated protein 4 (CTLA-4; an inhibitory molecule classically expressed on T cells) is now reported at an incidence of approximately 10%. Its pathogenesis is unknown, in part because no pathologic examination of the pituitary gland has been reported to date. We analyzed at autopsy the pituitary glands of six cancer patients treated with CTLA-4 blockade, one with clinical and pathologic evidence of hypophysitis, one with mild lymphocytic infiltration in the pituitary gland but no clinical signs of hypophysitis, and four with normal pituitary structure and function. CTLA-4 antigen was expressed by pituitary endocrine cells in all patients but at different levels. The highest levels were found in the patient who had clinical and pathologic evidence of severe hypophysitis. This high pituitary CTLA-4 expression was associated with T-cell infiltration and IgG-dependent complement fixation and phagocytosis, immune reactions that induced an extensive destruction of the adenohypophyseal architecture. Pituitary CTLA-4 expression was confirmed in a validation group of 37 surgical pituitary adenomas and 11 normal pituitary glands. The study suggests that administration of CTLA-4 blocking antibodies to patients who express high levels of CTLA-4 antigen in the pituitary can cause an aggressive (necrotizing) form of hypophysitis through type IV (T-cell dependent) and type II (IgG dependent) immune mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=84995906230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995906230&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2016.08.020

DO - 10.1016/j.ajpath.2016.08.020

M3 - Article

C2 - 27750046

AN - SCOPUS:84995906230

VL - 186

SP - 3225

EP - 3235

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 12

ER -